Cargando…
Primary Prophylaxis Lapelga(®) in Early Breast Cancer: A Real-World Experience
Background: Lapelga(®) was approved by Health Canada as a pegfilgrastim biosimilar in 2019 and remains the most commonly used biosimilar in Ontario and is fully reimbursed under the Ontario Drug Benefit program in this category. We explored the efficacy and tolerability of Lapelga(®) in a retrospect...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047890/ https://www.ncbi.nlm.nih.gov/pubmed/36975457 http://dx.doi.org/10.3390/curroncol30030244 |